Evidence map›Paper›PMID 36951508›Full record

ArticleCancer medicine2023

Continuity of care and advanced prostate cancer.

Ravishankar Jayadevappa, Thomas Guzzo, Neha Vapiwala, Stanley Bruce Malkowicz, Joseph J Gallo, Sumedha Chhatre

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ravishankar JayadevappaDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-2638-0051
Thomas GuzzoDivision of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Neha VapiwalaAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Stanley Bruce MalkowiczDivision of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Joseph J GalloSchool of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Sumedha ChhatreLeonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-4718-0198
Philadelphia VA Medical Center · USUniversity of Pennsylvania · USJohns Hopkins University · US

Funding

Provider Characteristics and Quality of Prostate Cancer CareR01HS024106 · AHRQ · UNIVERSITY OF PENNSYLVANIA · PI JAYADEVAPPA, RAVISHANKAR · 2015 to 2018
$923k
AHRQ HHS R01 HS024106
6 · The paper itself

Abstract

backgroundContinuity of care is an important element of advanced prostate cancer care due to the availability of multiple treatment options, and associated toxicity. However, the association between continuity of care and outcomes across different racial groups remains unclear.

objectiveTo assess the association of provider continuity of care with outcomes among Medicare fee-for-service beneficiaries with advanced prostate cancer and its variation by race.

designRetrospective cohort study using Surveillance, Epidemiology, and End Results (SEER)-Medicare data. SUBJECTS: African American and white Medicare beneficiaries aged 66 or older, and diagnosed with advanced prostate cancer between 2000 and 2011. At least 5 years of follow-up data for the cohort was used. MEASURES: Short-term outcomes were emergency room (ER) visits, hospitalizations, and cost during acute survivorship phase (2-year post-diagnosis), and mortality (all-cause and prostate cancer-specific) during the follow-up period. We calculated continuity of care using Continuity of Care Index (COCI) and Usual Provider Care Index (UPCI), for all visits, oncology visits, and primary care visits in acute survivorship phase. We used Poisson models for ER visits and hospitalizations, and log-link GLM for cost. Cox model and Fine-Gray competing risk models were used for survival analysis, weighted by propensity score. We performed similar analysis for continuity of care in the 2-year period following acute survivorship phase.

resultsOne unit increase in COCI was associated with reduction in short-term ER visits (incidence rate ratio [IRR] = 0.65, 95% confidence interval [CI] 0.64, 0.67), hospitalizations (IRR = 0.65, 95% CI 0.64, 0.67), and cost (0.64, 95% CI 0.61, 0.66) and lower hazard of long-term mortality. Magnitude of these associations differed between African American and white patients. We observed comparable results for continuity of care in the follow-up period.

conclusionsContinuity of care was associated with improved outcomes. The benefits of higher continuity of care were greater for African Americans, compared to white patients. Advanced prostate cancer survivorship care must integrate appropriate strategies to promote continuity of care.

Indexed as

MedicareProstatic NeoplasmsAgedContinuity of Patient CareHumansMaleProportional Hazards ModelsRetrospective StudiesUnited Statesadvanced prostate cancercontinuity of carecost of carehealth service usemortalityracial disparitySEER-Medicare database

Identifiers

PMID36951508
PMCPMC10242338
OpenAlexW4360601023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.